Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
The company distributes its products through third-party distributors. It has collaborations with F.
Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 20, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,055 |
| CEO | Matthew Klein |
Contact Details
Address: 100 Corporate Court South Plainfield, New Jersey 07080 United States | |
| Phone | 908 222 7000 |
| Website | ptcbio.com |
Stock Details
| Ticker Symbol | PTCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070081 |
| CUSIP Number | 69366J200 |
| ISIN Number | US69366J2006 |
| Employer ID | 04-3416587 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, Senior Consultant and Member of Scientific Advisory Board |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Independent Director |
| Pierre Gravier M.S. | Chief Financial Officer |
| Mark Elliott Boulding J.D. | Executive Vice President and Chief Legal Officer |
| Eric Pauwels | Chief Business Officer |
| Dr. Lee Golden M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Christine Utter CPA | Senior Vice President, Chief Accounting Officer and Head of People Services |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Linda Montella Carter | Senior Vice President and Chief Information Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 144 | Filing |
| Dec 3, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 144 | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |